01:30 PM EDT, 05/06/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We trim our 12-month target price to $179 from $209, reflecting a 5.8x multiple of our 2025 sales estimate, a discount to INSP's five-year historical forward average due to investor concerns related to the future impact of GLP-1 drugs. We lift our 2025 EPS forecast by $0.10 to $2.26 and in 2026 by $0.06 to $3.20. INSP posted Q1 EPS of $0.10 vs. -$0.34, beating the S&P Capital IQ consensus estimate by $0.33. INSP delivered strong Q1 results, with revenue growth of 23% Y/Y (3% above consensus), driven primarily by robust U.S. sales expansion. Operating margins reached $33.2M, nearly tripling from $11.9M in Q1 2024. On the tariff front, INSP's products are currently sourced and assembled primarily in the U.S., leaving exposure to recently implemented tariff policies as de minimis. Looking forward, INSP increased its 2025 EPS guidance by $0.10 to a $2.20-$2.30 range, reflecting growing confidence in its profitability trajectory. We think the full launch of the Inspire V system in May will help boost the company's growth.